Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Threat of new entrants • Market condition PART 08: MARKET SEGMENTATION BY DRUG CLASS • Segmentation by drug class • Comparison by drug class • Global beta blockers market • Global ARBs market • Global ACE inhibitors market • Global others market • Market opportunity by drug class PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Heart failure drugs market in Americas • Heart failure drugs market in EMEA • Heart failure drugs market in APAC • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Growing strategic alliances • Investment inclination toward developing countries PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive landscape PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Amgen • AstraZeneca • Bayer • Novartis PART 16: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Heart function, before and after heart failure Exhibit 02: Factors causing heart failure Exhibit 03: Stages of heart failure Exhibit 04: Major treatment options for various stages of heart failure Exhibit 05: Global heart failure rate 2015 Exhibit 06: Parent market Exhibit 07: Market characteristics Exhibit 08: Market segments Exhibit 09: Market definition: Inclusions and exclusions checklist Exhibit 10: Market size 2017 Exhibit 11: Validation techniques employed for market sizing 2017 Exhibit 12: Global heart failure drugs market 2017-2022 ($ millions) Exhibit 13: Global heart failure drugs market: Year-over-year growth 2018-2022 (%) Exhibit 14: Five forces analysis 2017 Exhibit 15: Five forces analysis 2022 Exhibit 16: Bargaining power of buyers Exhibit 17: Threat of new entrants Exhibit 18: Market condition: Five forces 2017 Exhibit 19: Global heart failure drugs market by drug class 2017-2022 (%) Exhibit 20: Comparison by drug class Exhibit 21: Global beta blockers market 2017-2022 ($ millions) Exhibit 22: Common beta blockers used for CVDs Exhibit 23: Global beta blockers market: Year-over-year growth 2018-2022 (%) Exhibit 24: Global ARBs market 2017-2022 ($ millions) Exhibit 25: Global ARBs market: Year-over-year growth 2018-2022 (%) Exhibit 26: Global ACE inhibitors market 2017-2022 ($ millions) Exhibit 27: Adverse effects of ACE inhibitors Exhibit 28: Global ACE inhibitors market: Year-over-year growth 2018-2022 (%) Exhibit 29: Global others market 2017-2022 ($ millions) Exhibit 30: Global others market: Year-over-year growth 2018-2022 (%) Exhibit 31: Market opportunity by drug class Exhibit 32: Customer landscape Exhibit 33: Global heart failure drugs market by geography 2017-2022 (%) Exhibit 34: Regional comparison Exhibit 35: Heart failure drugs market in Americas 2017-2022 ($ millions) Exhibit 36: Heart failure drugs market in Americas: Year-over-year growth 2018-2022 (%) Exhibit 37: Heart failure drugs market in EMEA 2017-2022 ($ millions) Exhibit 38: Heart failure drugs market in EMEA: Year-over-year growth 2018-2022 (%) Exhibit 39: Heart failure drugs market in APAC 2017-2022 ($ millions) Exhibit 40: Top Asian countries in terms of population with diabetes Exhibit 41: Heart failure drugs market in APAC: Year-over-year growth 2018-2022 (%) Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: World population by age group 2015-2050 (millions) Exhibit 45: Percentage of population aged 65 and above by region 2015 and 2050 Exhibit 46: Major complications of diabetes Exhibit 47: Global obesity facts 2014 Exhibit 48: Percentage of workday spent walking or standing versus sitting in selected occupation 2016 Exhibit 49: Side effects of the drugs used in heart failure treatment and management Exhibit 50: Demographic and economic snapshot of India and China Exhibit 51: Vendor landscape Exhibit 52: Landscape disruption Exhibit 53: Competitive structure analysis of global heart failure drugs market Exhibit 54: Vendors covered Exhibit 55: Vendor classification Exhibit 56: Market positioning of vendors Exhibit 57: Amgen: Vendor overview Exhibit 58: Amgen: Business segments Exhibit 59: Amgen: Organizational developments Exhibit 60: Amgen: Geographic focus Exhibit 61: Amgen: Segment focus Exhibit 62: Amgen: Key offerings Exhibit 63: AstraZeneca: Vendor overview Exhibit 64: AstraZeneca: Business segments Exhibit 65: AstraZeneca: Organizational developments Exhibit 66: AstraZeneca: Geographic focus Exhibit 67: AstraZeneca: Segment focus Exhibit 68: AstraZeneca: Key offerings Exhibit 69: Bayer: Vendor overview Exhibit 70: Bayer: Business segments Exhibit 71: Bayer: Organizational developments Exhibit 72: Bayer: Geographic focus Exhibit 73: Bayer: Segment focus Exhibit 74: Bayer: Key offerings Exhibit 75: Novartis: Vendor overview Exhibit 76: Novartis: Business segments Exhibit 77: Novartis: Organizational developments Exhibit 78: Novartis: Geographic focus Exhibit 79: Novartis: Segment focu Exhibit 80: Novartis: Key offerings

Amgen, AstraZeneca, Bayer, Novartis, Gilead, GlaxoSmithKline, Pfizer, and Teva Pharmaceutical industries.